Abstract 11022: Aspirin with Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention; A Cost per Outcome Analysis

Gal Tsaban,Hilmi Alnsasra,Ala Abu Dogosh,Itai Weissberg,Yael Ben-Baruch Golan,Orit Barrett,Roi Westreich,Enis Aboalhasan,Ariel Hammerman,Joseph Azuri,Ronen Arbel

Abstract 11022: Aspirin with Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention; A Cost per Outcome Analysis

2021

Gal Tsaban
Hilmi Alnsasra
Ala Abu Dogosh
Itai Weissberg
Yael Ben-Baruch Golan
Orit Barrett
Roi Westreich
Enis Aboalhasan
Ariel Hammerman
Joseph Azuri
Ronen Arbel

Introduction: Secondary prevention of cardiovascular events among patients with diagnosed cardiovascular disease and high ischemic risk poses a significant challenge in clinical practice. Both Tica...

Keywords:

Rivaroxaban
Disease
outcome analysis
Ticagrelor
High Ischemic Risk
low dose
secondary prevention
Aspirin
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations